Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma

Antitumor and Anti-inflammatory Effects of Trabectedin on Human Myxoid Liposarcoma Cells

(2010) G. Germano et al.   CANCER RESEARCH

Novel Models of Myxoid Liposarcoma Xenografts Mimicking the Biological and Pharmacologic Features of Human Tumors

(2010) R. Frapolli et al.   CLINICAL CANCER RESEARCH

Trabectedin therapy for sarcomas

(2010) Paolo G Casali et al.   CURRENT OPINION IN ONCOLOGY

A Review of Trabectedin (ET-743): A Unique Mechanism of Action

(2010) Maurizio D'Incalci et al.   MOLECULAR CANCER THERAPEUTICS

Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer

(2009) J. M. Del Campo et al.   ANNALS OF ONCOLOGY

Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series

(2009) F. Grosso et al.   ANNALS OF ONCOLOGY

Trabectedin: an anticancer drug from the sea

(2009) Kristen N Ganjoo et al.   EXPERT OPINION ON PHARMACOTHERAPY

Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules

(2009) George D. Demetri et al.   JOURNAL OF CLINICAL ONCOLOGY

Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors

(2009) C. Forni et al.   MOLECULAR CANCER THERAPEUTICS

Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma

(2008) Patrick Schöffski et al.   EXPERT OPINION ON PHARMACOTHERAPY

Neoadjuvant Treatment of Locally Advanced Soft Tissue Sarcoma of the Limbs: Which Treatment to Choose?

(2008) P. Hohenberger et al.   ONCOLOGIST